Table 2. AEs of any grade occurring in ≥20% of patients and grade ≥3 AEs occurring in ≥10% of patients in combination treatment.

AEs	n (%)
	Total			Chidamide 20 mg (N=9)			Chidamide 25 mg (N=9)			Chidamide 30 mg (N=9)			Chidamide 35 mg (N=3)
	Any grade	Grade ≥3		Any grade	Grade ≥3		Any grade	Grade ≥3		Any grade	Grade ≥3		Any grade	Grade ≥3
AE, adverse event.
Neutropenia	30 (100)	25 (83.3)		9 (100)	8 (88.9)		9 (100)	6 (66.7)		9 (100)	9 (100)		3 (100)	2 (66.7)
Leukopenia	29 (96.7)	27 (90.0)		9 (100)	9 (100)		8 (88.9)	6 (66.7)		9 (100)	9 (100)		3 (100)	3 (100)
Nausea	22 (73.3)	0 (0)		8 (88.9)	0 (0)		5 (55.6)	0 (0)		6 (66.7)	0 (0)		3 (100)	0 (0)
Alopecia	20 (66.7)	0 (0)		9 (100)	0 (0)		4 (44.4)	0 (0)		6 (66.7)	0 (0)		1 (33.3)	0 (0)
Anemia	19 (63.3)	2 (6.7)		8 (88.9)	0 (0)		3 (33.3)	0 (0)		5 (55.6)	1 (11.1)		3 (100)	1 (33.3)
Vomiting	18 (60.0)	4 (13.3)		6 (66.7)	1 (11.1)		6 (66.7)	0 (0)		5 (55.6)	3 (33.3)		1 (33.3)	0 (0)
Thrombocytopenia	17 (56.7)	3 (10.0)		4 (44.4)	1 (11.1)		4 (44.4)	1 (11.1)		7 (77.8)	1 (11.1)		2 (66.7)	0 (0)
Fatigue	12 (40.0)	0 (0)		3 (33.3)	0 (0)		5 (55.6)	0 (0)		4 (44.4)	0 (0)		0 (0)	0 (0)
Peripheral sensory neuropathy	11 (36.7)	0 (0)		4 (44.4)	0 (0)		1 (11.1)	0 (0)		5 (55.6)	0 (0)		1 (33.3)	0 (0)
Decrease appetite	10 (33.3)	1 (3.3)		5 (55.6)	0 (0)		2 (22.2)	1 (11.1)		2 (22.2)	0 (0)		1 (33.3)	0 (0)
Increased alanine aminotransferase	9 (30.0)	0 (0)		2 (22.2)	0 (0)		4 (44.4)	0 (0)		3 (33.3)	0 (0)		0 (0)	0 (0)
Hypertriglyceridemia	7 (23.3)	0 (0)		2 (22.2)	0 (0)		1 (11.1)	0 (0)		2 (22.2)	0 (0)		2 (66.7)	0 (0)
Hypoalbuminemia	6 (20.0)	0 (0)		1 (11.1)	0 (0)		1 (11.1)	0 (0)		3 (33.3)	0 (0)		1 (33.3)	0 (0)
Influenza	6 (20.0)	0 (0)		0 (0)	0 (0)		3 (33.3)	0 (0)		3 (33.3)	0 (0)		0 (0)	0 (0)
Pyrexia	6 (20.0)	0 (0)		4 (44.4)	0 (0)		0 (0)	0 (0)		2 (22.2)	0 (0)		0 (0)	0 (0)
Febrile neutropenia	3 (10.0)	3 (10.0)		2 (22.2)	2 (22.2)		0 (0)	0 (0)		1 (11.1)	1 (11.1)		0 (0)	0 (0)